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Antiretroviral therapy (ART) is not curative as HIV-1 persists in long-lived viral reservoirs.
Consequently, patients are dependent on life-long drug adherence with possible side
effects. To overcome these limitations strategies of a functional cure aim at ART free viral
remission. In this study, we sought to identify detailed subsets of anti-viral CD8+ T cell
immunity linked to natural long-term control of HIV-1 infection. Here, we analyzed HIV
controllers and ART suppressed progressors for in vitro viral suppressive capacity (VSC)
at baseline and after peptide stimulation. Functional properties and phenotypes of CD8+ T
cells were assessed by IFN-g ELISPOT and 18 color flow cytometry. HIV controllers
showed significantly increased suppression at baseline as well as after peptide
stimulation. IFN-g secretion and the proliferation marker Ki67 positively correlated with
VSC. Moreover, the detailed phenotype of three distinct multifunctional memory CD8+ T
cell subsets were specific traits of HIV controllers of which two correlated convincingly with
VSC. Our results underline the importance of multifunctional CD8+ T cell responses during
natural control. Especially the role of CXCR5 expressing cytotoxic subsets emphasizes
potential surveillance in sites of reservoir persistence and demand further study.
Keywords: HIV controllers, functional cure, viral suppressive capacity, multifunctional CD8+ T cells, CXCR5 CD8 T
cells + +, elite controllersINTRODUCTION
Antiretroviral therapy (ART) halts the progression to AIDS by suppressing viral replication but is not
curative, because HIV-1 persists in long-lived latent reservoirs (1–3). Interestingly a small group of
HIV-1 infected patients succeeds in maintaining low plasma viral loads (pVL) over many years in the
absence of therapy. They are regarded as the role model for a functional cure, which refers to ART free
HIV-1 remission. HIV controllers are subdivided according to their level of viremia into elite
controllers (EC), with pVL < 20 copies, and viremic controllers (VC), with pVL ≤ 2000 copies (4). The
association of EC with certain HLA-I alleles is one of the strongest indications for an involvement of
anti-viral CD8+ T cells (5–7). An abundance of literature has characterized the anti-HIV-1 CD8 + Torg February 2021 | Volume 11 | Article 6223431
Adams et al. Multifunctional CD8+ T Cellscell response in EC displaying greater cytotoxicity (8, 9), higher
proliferation (10, 11) and polyfunctionality (12, 13). There is
strong evidence that specificity, quality and broadness are all key
determinants of efficient HIV-1- specific CD8+ T-cell mediated
responses (14). Also do a number of functional studies substantiate
that protection against HIV-1 is more related to the quality (such
as polyfunctionality) of the T cell response than to its magnitude
(15). Moreover higher frequencies of early T cell responses
preferentially targeting the Gag protein are predictive of low
viral set point, control of infection and found to be dominant in
EC (16–18). Among other aspects, targeting Gag constraints
immune escape as it comes with high costs in viral fitness when
mutated (19, 20). Therefore eliciting polyclonal T cell responses
targeting conserved epitopes in Gag is a major objective in HIV
vaccinology (21).
HIV controllers are a heterogeneous population. Potent anti-
HIV-1 CD8+ T cell responses are not restricted to HIV
controllers carrying protective HLA alleles. Moreover very
weak HIV-1-specific T cell responses can be found in HIV
controllers while non-HIV controllers may present with such
favorable genetic background (22, 23). Taken together, these
finding indicate that additional factors may contribute to achieve
sustained viral control (24).
Direct evidence for viral suppressive capacity (VSC) in vitro is
derived from the viral inhibition assay (VIA), which measures
viral outgrowth from CD4+ T cells in the presence of CD8+ T
cells. Several studies highlighted improved VSC in EC compared
to progressors (9, 25, 26). The breadth of Gag CD8+ T cell
responses was found to be associated with higher VSC and
reduced viral loads in vivo (27, 28). Interestingly low VSC
predicts CD4+ T cell decline in untreated patients (29). We
recently reported that VSC after peptide stimulation was
correlated in ART-treated patients with higher expression of
immune checkpoint markers on subsets of terminally
differentiated effector memory (TEMRA) CD8+ T cells
producing higher level of IFN-g, TNF-a and IL-10 (30).
However to understand which specific CD8+ T-cell subsets are
most effective in viral suppression of HIV controllers is
still needed.
Over the last years secondary lymphoid organs were
pinpointed as the major anatomical sites of HIV persistence
during ART (31). Recent studies highlighted the importance of
lymph node resident follicular CD4 + T helper cells for ongoing
viral replication correlating with the presence CD8+ T cell (32).
Further data from SIV infection suggest a functional role of B-
cell follicle homing CD8+ T cells (CXCR5+) that could contribute
to control SIV infection (33). To what degree CXCR5+CD8+ T
cells are present in EC and which functional phenotype they have
remains to be clarified.
To that aim, we performed an in-depth characterization of
CD8+ T cells after expansion of Gag-specific memory responses.
We identified three distinct multifunctional subsets in natural
controllers associated with strong CD8+ T-cell responses and
VSC. For the first time, we report the emergence of CXCR5
cytotoxic subsets from peripheral blood of EC that might target
the productive HIV-1 reservoir.Frontiers in Immunology | www.frontiersin.org 2MATERIAL AND METHODS
Study Design and Participants
A total of 56 patients were recruited in the Belgian clinical AIDS
Reference Centers of Antwerp (Institute of tropical medicine),
Brussels (Centre Hospitalière Universitaire Sint Pierre and
Universitair Ziekenhuis Brussels), Liège (Centre Hospitalière
Universitaire) and Hasselt (Jessa Ziekenhuis). Inclusion criteria
defined elite controller (EC) as being treatment naïve, pVL ≤ 20
copies/ml with a duration ≥ 12 months; viral controller (VC) as
treatment naïve, pVL 20–2000 copies/ml with a duration ≥ 12
months; ART as patients under treatment, pVL ≤ 20 copies/ml
for ≥ 24 months. The numbers of patients in the different
categories were as follows: EC (n=15), VC (n=11), ART
(n=30). Although not set as a inclusion criterium it is worth to
mention that all patients had stable CD4+ T cell counts above 500
cells/mm3. Patients signed informed consent for longitudinal
blood donation of 100 ml every 6 months over a period of 3
years. The study was approved by each local ethical committee
and received the ethical approval from the university hospital of
Antwerp (Belgium) under the registration number:
B300201731330 as a multicenter Belgian cohort called as
PhenoCure. Furthermore, anonymized blood samples from
healthy donors (HD) (seronegative for HIV, HBV, and HCV)
were collected from the red cross in Luxembourg as controls for
certain immune assays.
Blood was processed within a maximum of 6 h to maintain
functionality of PBMCs. Whole blood separation was done by
gradient centrifugation using lymphoprep™ (Stemcell
technologies) and LeucoSEP™ (Greiner Bio-One) tubes
according to harmonized standard operating procedures.
Isolated PBMCs were cryopreserved in commercially available
medium (Cryostor, CS10, Stemcell technologies, Vancouver,
Canada) and stored in liquid nitrogen (-196°C). Plasma and
whole blood samples were stored at -80°C.
Viral Inhibition Assay
The viral inhibition assay was set-up as described previously with
significant modifications (34). CD4+ T cells and CD8+ T cells
were prepared and isolated from freshly thawed PBMCs
as follows:
Preparation of CD4+ T target cells: freshly thawed PBMCs
were stimulated with an anti-human CD3/CD8 bi-specific
monoclonal antibody (1µg/ml, NIH AIDS Reagent Program)
and cultured during 7 days in “R10/IL-2” medium, composed of
Rosewell Park Memorial Institute (RPMI) medium with 10%
fetal bovine serum (FBS), L-Glutamine (0,4 mM per ml),
supplemented with Penicillin and Streptomycin at 100 IU/ml
and interleukin-2 (IL-2 500 IU/ml, Gentaur, Kampenhout,
Belgium). PBMCs were cultured at a density of 2x106 cells per
ml at 37°C with 5% CO2. Fresh R10/IL-2 medium was added on
day 3 and 5 of culture. On day 7 cells were harvested, washed
three times with cold PBS (Gibco, Fisher Scientific, Waltham,
Massachusetts, USA) and CD4+ T cells were isolated using
negative selection magnetic beads (Miltenyi Biotech, San
Diego, California, USA) according to the manufacturer’sFebruary 2021 | Volume 11 | Article 622343
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confirmed by flow cytometry for CD3 (BUV496, clone OKT3),
CD4 (BUV395, clone SK3) and CD8 (BUV737, clone SK1).
Enriched cells were washed twice with R10/IL2 and then infected
with HIV IIIB lab strain (NIH AIDS reagent program) at a
multiplicity of infection of 10-3 using spinoculation at 1200 g for
2 h at 25°C followed by 1 h of incubation at 37°C 5% CO2. Cells
were washed twice with R10/IL2 and resuspended at 1 x 106cells per
ml in R10/IL2 medium to distribute for the VIA culture.
Preparation of CD8+ T effector cells: CD8+ T effector cells
were prepared in two conditions: stimulated (in vitro) and non-
stimulated (ex vivo). Freshly thawed PBMCs were stimulated
with a potential T cell epitope (PTE) Gag peptide pool (NIH
reagent program) at 100 ng/ml per peptide in R10 medium and
cultured for 7 days at 2 x 106 cells per/ml density without
changing the medium. For unstimulated cells freshly thawed
PBMCs were cultured overnight in R10 medium at 2 x 106cells
per/ml density. Both stimulated and unstimulated PBMCs were
harvested on the same day and subjected to CD8+ T cell negative
selection (Miltenyi Biotech, San Diego, California, USA). Purities
of more than 90% were confirmed by flow cytometry as
described above. Cells were washed twice with R10/IL2 and
resuspended at 1 x 106 cells per ml in R10/IL2 medium to
distribute for the subsequent VIA culture.
The VIA was performed in flat bottom 96-well culture plate
(Greiner BIO-ONE) in 200 µl volume of R10/IL2 medium. Each
patient sample was run in five conditions and each condition in
triplicates. The conditions were, non-stimulated and stimulated
CD8+ T effector cells in coculture with IIIb-infected CD4+ T
target cells at an effector-to-target (E:T) ratio of 1:1 and 1:10, as
well as IIIb-infected CD4 + T target cells only. Half of culture
medium was recovered and refreshed every 3 days. Specificity of
the assay was previously shown (30) and no further group of
uninfected controls was included during this study. Levels of p24
antigen in supernatants were quantified on day 14 in coculture
by p24 ELISA (BioMARIC, Ghent, Belgium) according to the
manufacturer’s protocol. VSC was calculated as log10 [p24 CD4
+
T cells only] – [p24 coculture with CD8+ T cells].
Measurement of Soluble Factors by
MULTI-ARRAY ELISA
Several cytokines and chemokines were assessed in plasma of
patients and at day 5 of the VIA coculture using two different
configurations of MULTI-ARRAY ELISA (mesoscale discovery,
Rockville, Maryland, USA) U-plex detection plates respectively.
On plasma we assessed IFN-g, TNF-a, IL1-b, IL-6, IL18, and
IP10. On supernatants from the VIA coculture we assessed IFN-
g, IL-2, IL6, IL-12p70, IP-10, TNF-a, TRAIL, CCL4 (MIP1b).
Technical procedures were executed according to the
manufacturer’s instructions and acquired on the MESO
SECTOR S600 (mesoscale discovery) reader.
ELISPOT for IFN-g Production
MultiScreenHTS-IP, 0,45µm, 96-well plates (Merck Millipore,
Burlington, Massachusetts, USA) were coated overnight with
anti-human IFN-g monoclonal antibody (clone 1-D1K,
MABTECH, Stockholm, Sweden) diluted 1/100 in PBS at 4°C.Frontiers in Immunology | www.frontiersin.org 3The next day plates were washed with PBS and then blocked with
R10 medium for 60 min. 2 x 105PBMCs/per well in 200 µl
volume were loaded onto the plate supplemented with PTE Gag
peptide pool (NIH reagent program) at 100 ng/ml concentration.
Samples were run in two conditions: 7 days Gag prestimulated
PBMCs and overnight rested non-stimulated PBMCs, each in
duplicates for a total duration of 36 h at 37°C 5% CO2. Duplicate
positive controls were stimulated with PMA (50 ng/ml,
Invivogen) and Ionomycin (500 ng/ml, Invivogen). PBMCs
from healthy donors were included as to estimate non-specific
background signal. After incubation plates were washed with
PBS and incubated with biotinylated IFN-g detection antibody
(clone 7-B6-1, MABTECH) diluted 1/100 PBS-0,05 Tween- 0,5%
BSA for 2 h. Revelation was performed using HRP Streptavidin
for ELISPOT (BD Biosciences) and AEC Substrate Set (BD
Biosciences) according to manufacturer’s instructions. Plates
were read and analyzed using Easy-Count and the SmartCount
(ImmunoSpot, Bonn, Germany) software.
Flow Cytometry
Detailed cellular phenotyping of PBMCs using 18-color flow
cytometry was performed just before the coculture and during
coculture (96 h into VIA culture). Before coculture, PBMCs were
evaluated in two conditions per patient. Either after 7 days of
prestimulation (stimulated condition) or after overnight resting
(Non-stimulated condition). Prior to staining both conditions
were exposed to PTE Gag peptides at 100 ng/ml per peptide for a
total of 16 h with Golgi Stop (1/1000 final dilution, BD Biosciences).
Golgi Plug (1/1000 final dilution) was added during the last 10 h of
culture together with anti-CD107a antibody (BV421, clone H4A3).
During the VIA coculture, prestimulated CD8+ T cells with
infected autologous CD4+ T cells or with non-infected
autologous CD4 + T cells at the 1:1 E:T ratio were analyzed
after 120 h (5 days) in coculture. Golgi Stop (1/1000 final
dilution, BD Biosciences), Golgi Plug (1/1000 final dilution)
and anti-CD107a antibody (BV421, clone H4A3) were added
into the culture 6 h before staining.
Cells were further harvested for antibody staining, washed twice
with 4 ml of FACS buffer (PBS with 1%BSA) and stained with the
LIVE/DEAD Fixable NearIR Dead cell stain kit (Thermo Fisher
Scientific) as well as the antibodies for the extracellular antigens for
30 min at 4°C. Subsequently cells were washed twice with 4 ml
FACS buffer and permeabilized/fixed using the FOXP3
transcription factor staining buffer set (eBioscience, Santa Clara,
California, USA) according to the manufacturer’s instructions. Next
the intracellular antigens were stained for 30 min. Cells were
washed twice with 4 ml of FACS Buffer and acquired on the
Fortessa LSR flow cytometer (BD Biosciences, USA).
Different panels were used for phenotyping sharing a common
backbone panel for lineage gating on T cells containing anti human
antibodies for CD4 (BUV395, clone SK3, BD), CD3 (BUV496,
clone UCHT1), CD8 (BUV737, clone SK1), CD45RA (BV460,
clone HI100), CXCR5(BV711, clone J52D4), CCR7 (PE-CF594,
clone 150305), CD14 (PECy5, clone G1D3), and LIVE/DEAD
Fixable NearIR Dead cell stain kit (APC-Cy7, Thermo Fisher
Scientific). The additional antibodies used in the panels were
anti-human: HLA-DR (BV510, clone L243), IL2 (BV605, cloneFebruary 2021 | Volume 11 | Article 622343
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4S.B3), PD-1 (BV786, clone EH12.1), Ki67 (Alexa Fluor 488,
clone B56), CD38 (PERCP-Cy5, clone HIT2), TNF-a (APC,
clone Mab11), IL-2 (PE, clone MQ1-17H12), Granzyme B
(PE, clone GB11), Perforin (PE-Cy7, clone B-D48), MIP-1b
(APC, clone D21-1351).
Quantification of HIV-1 DNA
Cell-associated HIV-1 DNA was isolated from purified CD4+ T
cells (CD4+ T cell microbeads, Miltenyi) from final quantities of
2x106 cells per patient. Extraction was done using the DNeasy
Blood and tissue kit (Qiagen, Hilden, Germany) according to
manufacturer’s instruction. Absolute quantification of HIV-1
DNA was performed by droplet digital PCR (ddPCR) (Bio-
Rad, Hercules, California) as previously described (35) with
total HIV-1 DNA primers and probes as reported (36).
Data Analysis and Statistics
Flow cytometry data were analyzed using Flow Jo (version 10, BD
Biosciences) and Kaluza (version 1.5, Beckman Coulter). Analysis
was done by a classical gating strategy focused hierarchically on
lymphocytes, single cells, live-cells, CD3+, CD8+ cells.
Subsequently CD8+ T cells were subdivided into the four main
subsets (Naïve (CD45RA+CCR7+), Central Memory (CM)
(CD45RA-CCR7+), Effector memory (EM) (CD45RA-CCR7-)
and terminally differentiated effector memory subsets re-
expressing CD45RA (TEMRA) (CD45RA+CCR7-). Subsequently
each subset was analyzed using a Boolean gating strategy
combining eight phenotypic and functional markers. Data was
exported as.csv files and imported into the Tableau (Tableau
Software, Seattle, Washington, USA) environment for data
cleaning and organization. Statistical testing was executed with
the QluCore (Qlucore, Scheelvägen, Sweden) software using
Kruskal Wallis non-parametric comparison with a false
discovery rate (FDR) of 0.2. Identified hits were exported into
Prism version 8 (GraphPad Software, California, USA) and
represented with from non-parametric multiple comparison
with Dunn’s correction.Frontiers in Immunology | www.frontiersin.org 4All other data was analyzed with Prism (version 8, GraphPad)
with non-parametric statistical methods tests (specified in figure
legends for each data set).RESULTS
Participants Demographics, Plasma
Markers, and Cell Associated HIV-1 DNA
The characteristics of HIV-1 patients recruited in the PhenoCure
cohort are given inTable 1. Inclusion criteria were mentioned in the
Material and Methods section defining the three categories.
Importantly, EC and VC were treatment naïve with the exception
of two female EC which have been ART-treated during pregnancy.
Information on the specific subtype of HIV-1 was not available for
all patients. With regard to plasma markers an elevated
concentration of circulating IL-18 in ART patients [median 534,8
pg/ml, (290,9–1478)] compared to EC [336 pg/ml, (149,1–412,1)]
was observed (Supplementary Figure 1A), suggesting that systemic
inflammation stays elevated during ART and in contrast is more
limited during natural control of HIV-1 infection. The other
cytokines (IL-6, IP-10, TNF-a) didn’t differ among patient groups
(Supplementary Figures 1B–D).
Cell-associated total HIV-1 DNA was significantly lower for EC
[median 124 copies/million CD4 + T cells, (46–2530)] compared to
the ART group [median 3680 copies/million CD4 + T cells, (208–
11146)] whereas the values for VC (median 185 copies/million
CD4 + T cells, [68-9648]) were not significantly different between
EC and ART-treated patient (Supplementary Figure 2A). These
findings are concordant to published literature (37).
Viral Suppressive Capacity Significantly
Increases by Gag Stimulation and Was
More Pronounced During Natural Control
of HIV-1 Infection
Increased VSC is commonly observed during in vivo viral
control. In the present study, two questions were addressed:February 2021 | Volume 11 | Article 622343t
TABLE 1 | Patient characteristics recruited in the PhenoCure cohort.
Category All EC VC ART
Number of individuals (n) 56 15 11 30
Median Age (years) 48 50 44 49
Range 27–69 34–69 27–65 28–68
Median CD4 counts (cells/µL) 863 937 936 778
Range 542–1980 712–1450 566–1980 542–1487
Median CD4 nadir (cells/µL) 552 665 647 299
Range 63–848 231–848 340–748 63–801
Median current pVL (copies/ml) >20 < 20 86 < 20
Range 19–1280 / 19–1280 /
Median highest pVL recorded prior to inclusion (copies/ml) 16800 < 20 182 469750
Range 19–10000000 19-11400 54–47800 5470 - 10000000
Median HIV-1 DNA (copies/million CD4) 1013 124 185 3680
Range 46–11146 46–285 68–9648 208–11146
Sex (percentage of male participants) 74% 40% 45% 80%All, all participants of the cohort; EC, elite controllers; VC, viral controllers; ART, ART treated patients.
Age (lifetime of participants in years); CD4 counts (Number of CD4+ T cells); CD4 nadir (lowest CD4 T cell count recorded); current pVL (plasma viral load at the time of analysis); highes
pVL recorded (highest plasma viral load recorded prior to inclusion into the cohort); HIV-1 DNA (total cell associated HIV-1 DNA in CD4+ T cells); Sex (sex of participants).
Adams et al. Multifunctional CD8+ T CellsFirst, to what extent will pre-stimulation with Gag peptides
improve VSC of CD8+ T cells compared to non-stimulated,
baseline VSC. Secondly, how this potential induction of VSC
compares among different clinical phenotypes, namely HIV
controllers (EC and VC) and treated progressors (ART). In
addition we ran VIA assays using two E:T ratios (1:1 and 1:10)
to estimate the per cell capacity of suppression. In the non-
stimulated (ex vivo) setting VSC in 1:1 ratios was significantly
increased for EC and VC as compared to ART (median VSC in
log10: EC 2.5, VC 2.02, ART 0.63). When the E:T ratio was
reduced (1:10), VSC was decreased so that no further difference
among groups was observed (Figure 1A) (median VSC in log10:
EC 0.47, VC 0.33, ART 0.29).
After Gag PTE stimulation (in vitro) for 7 days, VSC in EC
and VC was still significantly higher than in ART patients
(median VSC: EC 3.9, VC 3.6, ART 1.6.). Interestingly VSC
stayed significantly elevated for EC when ten times less effector
cells were present (Figure 1B) (median VSC: EC 2.4, VC 1.1,
ART 0.4). This points to a higher presence of HIV-1 specific T
cells or an increased per cell based ability to suppress viral
outgrowth. Interestingly stimulation with the Gag peptides
enhanced VSC in all patient groups (Figure 1C). The ratio of
enhancement for VSC stimulated over non-stimulated
condition (EC. 1.56, VC 1.78, ART 2.54) was the highest for
ART patients.
Collectively, these data underline the importance of anti-
Gag CD8+ T cell response for viral suppression across
different clinical phenotypes. EC and VC harbored a high
VSC already at baseline which further increased upon
stimulation. ART patients, did show significant increase
upon pre-stimulation as well raising the question which
aspects of T cell immunity delineate progressors from
controllers in this condition.
IFN-g Secretion Increases After
Stimulation and Correlates Moderately
With VSC
IFN-g secretion, measured by ELISPOT, is a hallmark of antiviral
immunity and is frequently used to assess the effect of T cell
vaccination strategies in clinical trials. In order to know whether
secretion of IFN-g does correlate with VSC we assessed the
number of spot-forming cells (SFC) in non-stimulated PBMCs
and Gag PTE-stimulated PBMCs. In both conditions, HD
PBMCs showed minimal responses, as expected; ART patients
showed a weak response as well (not significantly different from
HD), but enhanced by stimulation (Figure 2A). In EC the
response was heterogeneous but significantly increased from
VC and ART when PBMCs were not-stimulated (Figure 2A).
After stimulation for 7 days ELISPOT responses increased in all
patient groups as compared to their respective non-stimulated
condition (Wilcoxon paired rank test, EC: p < 0.0005, VC: p <
0.005 and ART: p< 0.005). The fold change of stimulated versus
non-stimulated (ratio of median values) condition per patient
group was: EC (2.25), VC (1,98), ART (2.84). Hence, the number
of IFN-g secreting cells increased most in ART patients. However
EC had still the highest total measures after peptide stimulationFrontiers in Immunology | www.frontiersin.org 5for 7 days (median SFC, EC: 392, VC: 214, ART: 151). Overall,
the number of IFN-y secreting cells did correlate moderately
with VSC for both conditions (Figures 2B, D).
Upon Gag Peptide Stimulation CD8+ T
Cells Increase Ki67 and CXCR5 but IFN-g
and CD107a Are Significantly Upregulated
in HIV Controllers Only
EC showed significantly increased production of IFN-g in CD8+
T cells after Gag PTE prestimulation compared with non-
stimulated PBMCs but also compared to other patient groups
(Figure 3A). Remarkably, pre-stimulation selectively enhanced
IFN-g production in EC and not in VC or ART (Figure 3A).
CD107a expression was similarly low in non-stimulated cells
from all groups but significantly increased in EC and VC after
pre-stimulation, although more pronounced in EC than in VC or
ART patients (Figure 3B). A similar trend was observed for
Ki67, a proliferation-associated marker, but the increase in
expression after pre-stimulation, was significant in all HIV(+)
subjects, including ART. However, EC showed significantly
higher percentages of Ki67 positive cells than VC and ART
(Figure 3C). Of note Ki67 in the ART group was also
significantly increased compared to uninfected, healthy
controls after peptide stimulation (p <0.05, not shown in the
graph) underlining GAG specific CD8+ T cell proliferation.
Interestingly an increase in CXCR5 was observed on CD8+ T
cells which was significant for EC and ART (Figure 3D). The
analysis of bulk CD8+ T cells showed no difference in Granzyme
B or Perforin (data not shown). There was no correlation with
VSC for IFN-g, CD107a and CXCR5. Ki67 correlated only
weakly with VSC (Supplementary Figure 3C). Overall, these
data showed that all HIV-1 patients respond to Gag stimulation
by upregulation of the proliferation marker, Ki67. IFN-g and
CD107a, however, were selective traits of HIV controllers.
EC Develop Distinct, Multifunctional, and
Cytotoxic CD8+ T Cell Subsets Upon
Stimulation of Which One Has Potential
Access to Lymph Node Follicles
To assess combined expression of phenotypical and functional
proteins of CD8+ T cells in detail we established a Boolean gating
strategy on the main memory and effector subsets. According to
these analyses, we found several rather unique multifunctional
subsets in EC (Figure 4). Two distinct subsets with a cytotoxic
profile expressing Ki67, IFN-g, CD107a, Perforin, and Granzyme
B were observed, in the effector memory (Figure 4A) and the
central memory compartment (Figure 4B). Both subsets were
nearly absent in VC or ART patients and correlated convincingly
with VSC (Figures 4A, B). Interestingly a third distinct subset
with expression of CXCR5 and cytotoxic markers was identified
(Figure 4C) which was significantly more prevalent in EC
compared to ART but did not correlate with VSC (Figure 4C).
Taken together, the identified subsets suggest the importance of
multiple distinct cytotoxic subsets during natural control of
HIV-1.February 2021 | Volume 11 | Article 622343
Adams et al. Multifunctional CD8+ T CellsSlight Increase in TNF-a but No Further
Differences in Cellular Phenotype nor
Soluble Factors During the Co-Culture
of VIA
To explore the mechanism of action by which CD8+ T cells
suppress viral outgrowth during VIA culture we performed flowFrontiers in Immunology | www.frontiersin.org 6cytometry at 120 h in co-culture (Figure 5). TNF-a showed a
slight but significant increase in EC compared to ART (Figure 5A)
but its expression did not correlate with VSC (data not shown).
For all other proteins, a strong expression of the proliferation
marker (Ki67), the effector molecule (Perforin) and terminal
differentiation marker (CD57) was detected in all patient groupsA
B
C
FIGURE 1 | Viral Suppressive capacity is highest in EC and significantly increased after peptide stimulation for all patient groups. Log10 inhibition of HIV p24
production measured for non-stimulated (A) and Gag PTE peptide pool (NIH) stimulated (B) CD8+ T cells towards superinfected autologous CD4+ T cells at E/T of
1:1 and 1:10. Statistical testing by non-parametric Kruskal Wallis with Dunn’s correction for multiple comparison. VSC compared between non-stimulated and
stimulated conditions for each patient group (C). Analysis by Mann Whitney non-parametric statistics. *<0.05, **<0.01, ***<0.001; ns: not significant.February 2021 | Volume 11 | Article 622343
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FIGURE 2 | IFN-g secretion is significantly increased in EC and correlates moderately with VSC. Overnight rested PBMCs were either ex vivo (Non-stimulated) (A) or
in vitro (Stimulated) with Gag PTE peptides for 7 days (C) before IFN-g secretion of PBMCs was measured by ELISPOT during 36 h in culture. Data plotted as spot
forming counts (SFC) and representative duplicates are shown as photos. Statistical analysis by Kruskal Wallis nonparametric statistics with correction for multiple
comparison by Dunn’s method. All HIV-1 infected patients were analyzed for correlation with VSC by Spearman’s rank correlation for Non-stimulated (B) and
Stimulated (D) PBMCs. *lt;0.05, **<0.01; ns: not significant.A B
DC
FIGURE 3 | CD8+ T cells of EC express significantly more IFN-g, CD107a, Ki67 and CXCR5 after peptide stimulation. Expression of IFN-y (A), CD107a (B), Ki67
(C), and CXCR5 (D) on CD8+ T cells ex vivo or Non-stimulated (light grey) and in vitro or Stimulated (dark grey). Statistical comparison by Kruskal Wallis with Dunn’s
correction for multiple comparison across groups. Paired Wilcoxon rank test comparison of non-stimulated versus stimulated conditions within groups. *<0.05,
**<0.01, ***<0.001; ns: not significant.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 11 | Article 6223437
Adams et al. Multifunctional CD8+ T Cells(Figure 5B). Especially the high levels of Perforin suggest an
involvement of direct cell to cell killing. PD-1 expression trended
higher in ART patients without any significance compared to viral
controllers (Figure 5B). Overall, besides TNF-a, single marker
expression levels did not show any significant differences between
patient groups. Furthermore, Boolean analysis of combinatorial
expression revealed no significant differences among clinical
phenotypes as well (data not shown). In addition, we assessed
the effect of in-vitro superinfection of CD4+ T cells on the CD8+ T
cells responses during coculture by comparing cocultures of non-Frontiers in Immunology | www.frontiersin.org 8superinfected CD4+ T cells with superinfected CD4+ T cells. We
did not detect any differences (Supplemental Figure 5).
Interestingly and although only assessed on a small number
patients, we observed a trending difference in CD8+ T cells co-
expressing Ki67, Perforin and IFN-g at only 48 h in coculture
(Supplementary Figure 6). In addition to these data we further
assessed soluble markers (IFN-g, IL-6, IP10, MIP-1b, TNF-a and
TRAIL) from the culture supernatants at 72 h in coculture with no




FIGURE 4 | CD8+ T cells of EC show multifunctional, cytotoxic profiles in effector and central memory compartment which correlate with viral suppression.
Phenotypes of CD8+ T cells were assessed upon stimulation for 7 days by flowcytometry. Combinatorial expression of different markers was analyzed by boolean
gating strategy. CD8+ effector memory T cells (CCR7-CD45RA-) in (A, C) and central memory T cells in (B) with respective spearman correlations with viral
suppression. The specific combination of expressed proteins is annotated below the graphs. Statistical testing in two steps, first the identification of hits by Kruskal
Wallis with a FDR of 0.2 followed by non-parametric Kruskal Wallis comparison with Dunn correction for multiple comparison. ***<0.001, ****<0.0001, ns: not
significant.February 2021 | Volume 11 | Article 622343
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Evidence for the importance of anti–HIV-1 CD8+ T cell
responses during natural control continues to substantiate. In
our study, we evaluated two aspects of in vitro viral suppression
in patients with natural control of HIV-1 infection and well-
treated progressors: the ex vivo “effector function” (unstimulated
condition) as well as the “memory function” (after in vitro
stimulation with Gag peptides for 7 days). We focused
specifically on the immune phenotypes of CD8+ T cells and
their functionality. While VSC did only weakly correlate with the
viral reservoir and not with the clinical parameters of the
patients, we observed a clear association with IFN-g secretion
and proliferation markers of CD8+ T cells. Furthermore, we
identified three cytotoxic subsets with different tissue homing
abilities specific for natural control of HIV-1. One of these GagFrontiers in Immunology | www.frontiersin.org 9reactive memory subsets expressed CXCR5 thus has potential
access to the B cell zone of lymphoid tissues. Overall, we show
that the use of a polyvalent Gag peptide pool induced a
significant increase of VSC in HIV-1 infected patients,
including treated progressors. However, multifunctional
cytotoxic CD8 T cell responses emerge in HIV controllers only
and hence might be key to sustained ART free HIV-1 control.
Several studies have reported elevated ex vivo VSC in EC
compared to progressors providing a direct link between control
of viremia and anti-viral CD8+ T cell immunity (9, 25, 26, 28, 38,
39). We observed a significant higher suppression of EC in non-
stimulated CD8+ T cells as well, however with a higher
heterogeneity across EC compared to other reports (Figure
1A). Interestingly the use of lower E:T ratio (1:10) abrogates
suppression of non-stimulated CD8+ T cells in our setting in
contrast to what Cirion et al. have reported. They observed theA
B
FIGURE 5 | CD8+ T cells of EC show slightly higher TNF-a production but overall no differences during coculture screening. TNF-a measured at 120 h in coculture
with representative flow charts (A). Heat Map depicting median expression of proteins in columns and patient group in rows with exact values plotted inside of the
cells of the heat map (B). Statistical testing by Mann Whitney nonparametric statistics. **<0.01; ns, not significant.February 2021 | Volume 11 | Article 622343
Adams et al. Multifunctional CD8+ T Cellssame level of VSC for HIV controllers in 1:1 and 1:10 ratios (38).
Possible reasons for these divergent findings could be the slightly
different technical setup for the VIA and different Gag peptide
pools for stimulation. In addition, the used cryopreserved
PBMCs could have introduced variance, although we applied
the widely established procedure of overnight resting for
functional studies on lymphocytes before use (40, 41), we
cannot rule out an effect of cryopreservation.
In contrast with most other studies we included VC and EC as
two distinctive groups of slow progressors. It has to be emphasized
that the current median pVL in this group was 86 copies/ml
(Table 1). Consequently at this low range a big proportion of these
patients was categorized as EC in the past when detection limits
for pVL were at 50 copies/ml or higher. Therefore, caution is
advised when relating our findings to the existing literature.
Secondly, most studies either do merge EC and VC or just look
at EC. As a result, studies on VC are comparably scarce. Our data
shows that VC excerpt comparable VSC to EC (Figure 1A). The
study from Spentzou et al. has reported similar results (34). This
suggests that slightly elevated pVLs do not reflect a loss of CD8+ T
cell suppression. Interestingly at the current understanding
elevated pVL could even contribute to the maintenance of anti-
viral CD8+ T cell responses because decreasing pVLs during the
initiation of ART associated with loss of VSC in progressors (39).
But for VC we did not find any correlation between pVL and VSC
(Supplementary Figure 4), suggesting that the level of viremia in
these patients does not reflect a loss or gain in CD8+ T
cell functionality.
In several previous studies Gag-specific CD8+ T cell responses
(measured by ELISPOT or flow cytometry) were inversely
correlated to viral load and were also described to be a major
contributor to increased VSC (27, 28, 42). We sought to investigate
the potential of 7 days Gag stimulation using the PTE Gag peptide
pool (NIH reagents program) across the different patient groups.
These peptides cover multiple overlapping sequences reflecting the
natural diversity of circulating HIV-1 strains (21). Consequently,
they offer a large antigenic breadth, the coverage of potential T cell
epitopes, and depth, the cross recognition of variants of epitopes.
Hence many of those are clustered in conserved regions (43–45).
Likewise, the importance of breadth in the anti-Gag response during
control of HIV-1 or SIV has been underscored (46, 47). To this end,
we hypothesized that expanding such memory T cells creates an
opportunity to delineate the decisive CD8+ T cell subsets of HIV
control. This because long lasting stimulation with conserved Gag
epitopes boosted VSC in progressors (30) and thus could allow to
identify detailed functional differences in T cell subsets compared
to controllers.
We observed that VSC increased with several orders of
magnitude significantly after stimulation with PTE Gag
peptides in all patient groups (Figure 1C). This strong effect
reflects their potency possibly rooted in the rapid recognition of
Gag epitopes as they can be presented on HLA-I molecules even
before viral integration (48, 49). The ability to redirect CTL
killing against reactivated autologous virus by Gag stimulation
was reported previously for EC and ART, however using IL2
during pre-stimulation of CD8 + T cells (50), which we omittedFrontiers in Immunology | www.frontiersin.org 10to not alter the phenotype of cells by exogenous cytokines and
reduce background noise in the VIA. Notably both controller
groups showed significantly higher VSC after peptide
stimulation as compared to ART (Figure 1B). This might be
rooted in an increased immunodominance of anti-Gag T cells of
controllers (51, 52), which could be further amplified by their
expansion. The significantly higher expression of Ki67, a
proliferation marker, on CD8+ T cells of EC could support this
hypothesis (Figure 3C). Importantly the proliferation of antigen
specific CD8+ T cells was associated to natural control by other
studies as well (10, 11). Shan et al. also observed increased
proliferation for ART patients in response to Gag peptides
(50), our data revealed significant higher expression of Ki67
pointing into a similar direction (Figure 3C). Next, we saw that
the VSC of EC after pre-stimulation with Gag PTE stayed
elevated even when E:T ratio is decreased to 1:10 (Figure 1B)
indicating a higher magnitude in Gag specific CD8+ T cell
expansion (as shown by higher Ki67 expression in EC) (Figure
3C) or a stronger per cell suppressive capacity.
To explore this aspect in detail we applied IFN-g ELISPOT at
baseline and after 7 days of peptide stimulation. ELISPOT results
clearly showed the increased frequency of IFN-g-secreting T cells
in PBMCs of EC at baseline and after prestimulation (Figures
2A, C). We observed only moderate correlation with VSC for
both conditions (Figures 2B, D). Other studies reported also
divergent results (28, 53). Interestingly an in vitro vaccination
study reported a correlation with IFN-g only when co-expressed
with CD107a and MIP-1b (54). This suggests that not IFN-g
alone but rather multifunctionality might be the best reflector of
increased VSC.
To explore functionality and phenotype on a single cell level we
phenotyped by 18 color flow cytometry without and after 7 days of
peptide stimulation. The expression of IFN-g in total CD8+ T cells
was significantly increased only after stimulation between EC and
VC and ART (Figure 3A). The degranulation marker CD107a
increased significantly for both groups, VC and EC (Figure 3B).
Interestingly Ki67 expression increased significantly in all three
groups which was suggestive of a specific HIV-1 proliferative
response to the Gag epitopes (Figure 3C), and corroborated by
its strict absence in HD controls (Figures 3A–C). Ki67 did show
moderate correlation with viral suppression in vitro.
Polyfunctional anti-viral CD8+ T cells, defined as “having the
ability to secrete chemokines and mediate cytolysis” (55), are a
qualitative feature of EC (18, 45, 56). To assess the combinatorial
expression of functional and phenotypic we applied a Boolean
gating strategy. By doing so, we identified three distinct subsets
significantly increased in EC. Two of those showed strong cytotoxic
characteristics (Figures 4A, B) from the EM and CM compartment
which correlated convincingly with VSC (Figure 4). This provides
evidence for the co-existence of multiple subsets that could be
implicated in HIV-1 control homing to central lymphoid organs
and peripheral tissues.
Intriguingly Gag peptide stimulation upregulated CXCR5 in
EC and ART patients (Figure 3D). Recent studies suggest that
circulating CXCR5+ CD8+ T cells are major producers of IL21 and
associate with limited HIV-1 replication (57). We cannot confirmFebruary 2021 | Volume 11 | Article 622343
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However a cytotoxic subset expressing CXCR5 with potential
access to the B cell follicles (Figure 4C) a major site of the viral
reservoir (58, 59) was significantly expanded in natural
controllers. Recent literature is controversial on the functionality
of these cells. Reuter et al. have reported a strong correlation
between CXCR5+ CD8+ T cells isolated from lymph node (LN)
and pVL in VC but a decreased killing ability compared to bulk
CD8+ T cells from PBMCs of the same patients (60). In contrast,
although Petrovas et al. observed a similar strong correlation with
pVL they find increased killing capacities of follicular CD8+ T cells
from LN as compared to CXCR5 negative counterparts despite
their compromised cytokine profile (61). To our knowledge, we
characterized for the first time a polyfunctional CD8+ T cell subset
combining features of cytotoxicity, proliferation and expressing
CXCR5 after expansion with Gag peptides. However we observed
no correlation with VSC (Figure 4C) that could be explained by
the low presence of this subset in blood. Still, this finding is of
utmost importance since follicular helper CD4+ T cells (TFH),
residing in B-cell follicles of secondary lymphoid tissues, represent a
major site of viral persistence (58). Future studies need to evaluate if
Gag specific CXCR5 positive subsets have suppressive abilities and
access to the LN of HIV controllers. Importantly, a recent study has
further substantiated that the predominant proportion of circulating
TCR repertoires in HIV-1 infected patients under ART is able to
target latent reservoirs (62). Future studies now should scrutinize
how to achieve proper qualitative features in such effector cells. In
conclusion, therapies boosting existing T cell immunity are a
potential angle of intervention but need to prove their potency in
vivo as resistance of reservoirs to complete elimination was a
concern raised earlier (63).
To elucidate the mechanism of HIV-1 CD8+ T cell mediated
suppression in vitro during the VIA coculture we phenotyped T
cells 120 h after the coculture when solid viral replication was
observed by intracellular P24 staining (data not shown). Only for
TNF-a we found a very minor increase which didn’t correlate with
VSC. Overall we could not identify any clear significant differences
between patient groups, but the strong increase of Perforin on total
CD8+ T cells of all patients (Figure 5B) suggests a direct cytotoxic
mechanism as previously proposed (9). Interestingly we detected
Perforin, IFN-g and Ki67 positive subsets at 48 h between EC and
ART (Supplementary Figure 6) in a subset of seven patients
suggesting that the assessment for phenotypic and functional
properties should be done earlier, before notable viral replication.
Furthermore, at 120 h in coculture the effect of exogenous IL-2
supplemented to the VIA media might have already levelled out
phenotypic differences between clinical phenotypes. A similar effect
might apply to the levels of cytokines or chemokines at 72 h in
coculture (Supplementary Figure 7). Overall the exact mechanism
of viral suppression in vitro remains to be determined.
In conclusion, our work demonstrated that stimulation with
polyvalent Gag peptide pools efficiently increased VSC in all patient
groups. Interestingly upregulation of CXCR5 expression was noted
upon pre-stimulation. The increased frequencies of several distinct
multifunctional CD8+ T cells subsets which correlated convincingly
with the magnitude of viral suppression is an particular attribute ofFrontiers in Immunology | www.frontiersin.org 11natural controllers. Furthermore Gag targeting CXCR5+CD8+ T
cells represent a unique subset of antiviral CD8+ T cells that may
play a pivotal role in the containment of reservoirs. Overall, our data
highlighted a multi-qualitative anti-Gag CD8+ T cell response
during control of HIV-1 that should be elicited for future
vaccination strategies to achieve ART free viral remission.DATA AVAILABILITY STATEMENT
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Supplementary Figure 1 | IL18 concentration in plasma differs significantly
between EC and ART. Plasma samples isolated during blood donation were
analyzed for the concentration of cytokines IL18 (A), IL-6 (B), IP-10 (C), and TNF-a
(D). Statistical testing by nonparametric Kruskal Wallis test with Dunn correction for
multiple comparison.Frontiers in Immunology | www.frontiersin.org 12Supplementary Figure 2 | HIV-1 DNA is significantly lower in EC compared to
ART and has a weak negative correlation with VSC over the whole cohort. Absolute
quantification of cell associated HIV-1 DNA on purified CD4 + T cells by ddPCR.
Five samples (A) (two of EC and three of VC measurements were below the
confidence interval of the negative control and cannot be accurately quantified.
These values have been excluded from the analysis to preclude statistical bias).
Testing was done with Kruskal Wallis nonparametric statistics with Dunn correction.
Spearman correlation of cell associated HIV-1 DNA with VSC on non-stimulated (B)
and stimulated (C) cells.
Supplementary Figure 3 | No correlation with IFN-g, CD107a, CXCR5 but a
weak correlation with Ki67 expression and VSC. Correlation of CD8+ T cell
expression of IFN-g (A), CD107a (B), Ki67 (C), and CXCR5 (D) with VSC. Non-
parametric rank spearman correlation with rho and p values are given in the figure.
Supplementary Figure 4 | No correlation of pVL with VSC of VC. Spearman
correlation of pVL with VSC for non-stimulated (A) and stimulated (B) CD8+ T cells
given for VC only because all other patients of the cohort have undetectable viremia.
Statistical values plotted in the graph.
Supplementary Figure 5 | No impact on the cellular phenotypes detected by
superinfection at 120 h in coculture. To assess if the superinfection with HIV-1 (IIIB)
has a detectable impact on the CD8+ T cell phenotypes we analyzed superinfected
and non-superinfected conditions separately by flow cytometry. No differences
were found as exemplified here for IFN-y (A) and CD107a (B) staining’s. Statistics
by paired Mann Whitney nonparametric testing.
Supplementary Figure 6 | A trend between EC and ART patients of Ki67,
Perforin, and IFN-g co-expressing CD8+ T cells at 48 h in coculture. To explore the
kinetic pattern of cytotoxic markers during coculture we phenotyped seven patients
at 48 h. Statistical testing by Mann-Whitney nonparametric comparison.
Supplementary Figure 7 | Concentration of cytokines at 3 days in VIA coculture
revealed no differences between patient groups. Supernatants of VIA coculture at
72 h (day 3) were tested with mutliplex ELISA for IFN-g (A), IL-6 (B), IP-10 (C),
MIP-1b (D), TNF-a (E), and TRAIL (F). Statistical testing by nonparametric Kruskal
Wallis test with Dunn correction for multiple comparison.REFERENCES
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28. Sáez-Cirión A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, et al.
Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers:
Association with Gag-Specific CD8 T Cell Responses. J Immunol (2009) 182
(12):7828–37. doi: 10.4049/jimmunol.0803928
29. Yang H, Wu H, Hancock G, Clutton G, Sande N, Xu X, et al. Antiviral
inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline
in HIV-1 infection. J Infect Dis (2012) 206(4):552–61. doi: 10.1093/infdis/
jis379
30. Pannus P, Adams P, Willems E, Heyndrickx L, Florence E, Rutsaert S, et al. In-
vitro viral suppressive capacity correlates with immune checkpoint marker
expression on peripheral CD8+ T cells in treated HIV-positive patients. AIDS
(2019) 33(3):387–98. doi: 10.1097/QAD.0000000000002068
31. Huang S-H, McCann CD, Mota TM, Wang C, Lipkin SM, Jones RB. Have
Cells Harboring the HIV Reservoir Been Immunoedited? Front Immunol
(2019). doi: 10.3389/fimmu.2019.01842
32. Reuter MA, Del Rio Estrada PM, Buggert M, Petrovas C, Ferrando-Martinez
S, Nguyen S, et al. HIV-Specific CD8+ T Cells Exhibit Reduced and
Differentially Regulated Cytolytic Activity in Lymphoid Tissue. Cell Rep
(2017). doi: 10.1016/j.celrep.2017.11.075
33. Mylvaganam GH, Rios D, Abdelaal HM, Iyer S, Tharp G, Mavinger M, et al.
Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection.
Proc Natl Acad Sci U S A (2017). doi: 10.1073/pnas.1621418114Frontiers in Immunology | www.frontiersin.org 1334. Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, et al. Viral
Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in
Clinical Trials of HIV-1 Vaccine Candidates. J Infect Dis (2010). doi:
10.1086/650492
35. Rutsaert S, De Spiegelaere W, Van Hecke C, De Scheerder MA, Kiselinova M,
Vervisch K, et al. In-depth validation of total HIV-1 DNA assays for
quantification of various HIV-1 subtypes. Sci Rep (2018). doi: 10.1038/
s41598-018-35403-6
36. Schvachsa N, Turk G, Burgard M, Dilernia D, Carobene M, Pippo M, et al.
Examination of real-time PCR for HIV-1 RNA and DNA quantitation in
patients infected with HIV-1 BF intersubtype recombinant variants. J Virol
Methods (2007). doi: 10.1016/j.jviromet.2006.11.012
37. Blankson JN, Bailey JR, Thayil S, Yang H-C, Lassen K, Lai J, et al. Isolation and
Characterization of Replication-Competent Human Immunodeficiency Virus
Type 1 from a Subset of Elite Suppressors. J Virol (2007). doi: 10.1128/
JVI.02165-06
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